Acute Kidney Injury (AKI) — Clinical Documentation Guide (2026)

🔍 1. Definition

Acute Kidney Injury (AKI) is a rapid decline in renal function occurring over hours to days, characterized by an abrupt increase in serum creatinine, decrease in urine output, or both. AKI represents a spectrum of injury from mild, reversible azotemia to severe renal failure requiring renal replacement therapy (RRT). Per the KDIGO 2012 Clinical Practice Guideline for Acute Kidney Injury, AKI is defined by any of the following criteria:

• Increase in serum creatinine (Cr) by ≥0.3 mg/dL within 48 hours
• Increase in serum Cr to ≥1.5× baseline within the prior 7 days
• Urine volume <0.5 mL/kg/h for ≥6 hours

For ICD-10-CM coding purposes, AKI is classified under category N17 (Acute kidney failure). A physician/provider diagnosis is required; coders and CDI specialists may not assign AKI solely on lab values without a documented diagnosis.

🗂️ 2. Alternative Terminology

Clinicians, nurses, and consultants use various terms for AKI. Coders must recognize all of the following as potentially codeable as N17.x (when documented by the treating provider):

🩺 3. Signs & Symptoms

AKI presents along a wide clinical spectrum. Early stages may be asymptomatic with only laboratory abnormalities, while advanced stages produce systemic manifestations of uremia and volume overload. Coders should note that signs and symptoms integral to a condition (e.g., oliguria in the setting of documented AKI) are not separately coded per ICD-10-CM Official Guidelines Section I.B.5.

• Oliguria/anuria — urine output <400 mL/24h (oliguria) or <100 mL/24h (anuria)
• Rising serum creatinine and BUN — azotemia
• Hyperkalemia — potentially life-threatening; may cause EKG changes and arrhythmias
• Metabolic acidosis — reduced bicarbonate, elevated anion gap
• Fluid overload — peripheral edema, pulmonary edema, hypertension
• Uremic symptoms — nausea, vomiting, anorexia, altered mental status (encephalopathy), pericarditis
• Hematuria / proteinuria — especially in glomerular etiologies
• Flank pain — in obstructive or vascular etiologies
• Electrolyte disturbances — hyperphosphatemia, hypocalcemia, hyponatremia

🧭 4. Differential Diagnosis

Accurate AKI coding depends on the provider's determination of etiology (pre-renal, intrinsic, or post-renal) and exclusion of conditions that mimic AKI. CDI specialists should prompt clarification when the etiology is ambiguous.

📋 5. Clinical Indicators for Coders/CDI

The following clinical indicators should prompt a CDI review or query for AKI. Coders should not assign N17.x without provider documentation; however, clinical indicators support query generation per AHIMA and ACDIS guidelines.

🦴 6. Anatomy & Pathophysiology

The kidneys are paired retroperitoneal organs responsible for filtration of approximately 180 liters of plasma per day via approximately 1 million nephrons each. The nephron — comprising the glomerulus, proximal convoluted tubule (PCT), loop of Henle, distal convoluted tubule, and collecting duct — is the functional unit affected in AKI.

Pre-renal AKI

Decreased renal perfusion due to true volume depletion (hemorrhage, GI losses, insensible losses), effective arterial blood volume depletion (heart failure, cirrhosis, sepsis), or medications (NSAIDs blunting prostaglandin-mediated afferent arteriolar dilation; ACE-I/ARBs blocking angiotensin II–mediated efferent arteriolar constriction). The GFR falls reversibly with no structural tubular damage initially. Prolonged pre-renal state converts to ischemic ATN.

Intrinsic AKI — Acute Tubular Necrosis (ATN)

ATN is the most common form of intrinsic AKI and the most frequently coded subtype (N17.0). It arises from:

• Ischemia: Sustained hypoperfusion causes tubular epithelial cell death, particularly in the highly metabolically active S3 segment of the PCT and thick ascending limb of Henle — both highly susceptible to oxygen deprivation.
• Nephrotoxins: Aminoglycosides (proximal tubule accumulation), IV contrast agents, cisplatin, amphotericin B, myoglobin (rhabdomyolysis), hemoglobin (hemolysis), and NSAIDs.

Pathophysiologically, tubular cell necrosis leads to intratubular obstruction by cellular debris, backleak of filtrate, and a reduction in GFR via tubuloglomerular feedback mechanisms.

Intrinsic AKI — Other Forms

• Acute cortical necrosis (N17.1): Diffuse ischemic necrosis of the renal cortex sparing the medulla; associated with obstetric catastrophes (abruptio placentae, PPH), septic shock, and DIC. High mortality; often irreversible.
• Acute medullary/papillary necrosis (N17.2): Ischemia of the renal papillae; classically associated with NSAID abuse, sickle cell disease, DM, analgesic nephropathy, and urinary tract obstruction.
• Interstitial nephritis (N10): Immune-mediated tubulointerstitial inflammation; drug reactions (beta-lactams, PPIs, NSAIDs), infections, or autoimmune.

Post-renal AKI

Urinary tract obstruction at any level (ureteral, bladder outlet, or urethral) causes increased intratubular pressure transmitted back to Bowman's space, reducing GFR. Common causes include BPH, prostate cancer, retroperitoneal fibrosis, bilateral ureteral obstruction, and obstructed urinary catheter. Rapid decompression is key to recovery.

KDIGO Staging — Clinical Reference

The KDIGO AKI staging system is the clinical standard used by providers. ICD-10-CM does not have stage-specific codes within N17, but KDIGO stage should inform CDI queries and MS-DRG severity capture:

💊 7. Medication Impact / Treatment

Pharmacologic management of AKI is primarily supportive. Several medication classes are directly implicated in AKI causation and must be documented by providers as drug-induced nephropathy to allow appropriate ICD-10-CM coding of drug-adverse effect or underdosing codes per ICD-10-CM Guideline I.C.19.e.

Nephrotoxic Medications (Causative of AKI)

Supportive Pharmacologic Management (AKI Treatment)

• Loop diuretics (furosemide, bumetanide): Convert oliguric to non-oliguric AKI; facilitate fluid management; do NOT improve recovery or mortality in ATN.
• Vasopressors (norepinephrine, vasopressin): Maintain MAP ≥65 mmHg in sepsis-associated AKI; vasopressin preferred in hepatorenal syndrome (with albumin).
• Erythropoiesis-stimulating agents (ESAs): Epoetin alfa (J0885), darbepoetin (J0881) for anemia of CKD context post-AKI; HCPCS codes relevant for ESRD-associated management.
• IV Iron (ferric carboxymaltose — J1439; ferumoxytol — J0596; iron sucrose — J1756): Adjunct to ESA therapy in ESRD/CKD setting.
• Sodium bicarbonate: Manages metabolic acidosis; used prophylactically for contrast nephropathy.
• N-Acetylcysteine (NAC): Prophylaxis for contrast nephropathy (evidence mixed; still commonly ordered).
• Kayexalate / Patiromer / Sodium Zirconium Cyclosilicate (SZC): Management of AKI-associated hyperkalemia.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides